10-Q: Neurocrine Biosciences Q1 2026 Earnings Surge on Strong Sales

Neurocrine Biosciences reported a significant increase in net income and revenue for the first quarter of 2026, driven by robust sales of INGREZZA and CRENESSITY, alongside progress in its development pipeline and a major acquisition.

Summary

• Neurocrine Biosciences reported a substantial increase in net income to $197.9 million for the first quarter of 2026, a significant jump from $7.9 million in the same period last year.
• Total revenues grew by 43.9% to $814.5 million, primarily due to a 43% increase in net product sales to $811.0 million.
• INGREZZA net product sales reached $656.9 million, up from $545.2 million in Q1 2025, while CRENESSITY sales were $153.3 million, up from $14.5 million following its launch in December 2024.
• Operating expenses increased to $621.1 million from $549.0 million, with R&D expenses rising to $296.2 million and SG&A expenses increasing to $318.5 million.
• The company completed the sale of Neurocrine Group Limited for $63.2 million, recognizing a pre-tax gain of $28.6 million.
• A significant development is the announced Agreement and Plan of Merger to acquire Soleno Therapeutics, Inc. for approximately $2.9 billion, with a tender offer commenced in April 2026.
• Cash flow from operations was $145.8 million, an increase from $64.8 million in the prior year, though investing activities showed a net outflow of $506.2 million due to debt security purchases.
• The company ended the quarter with $266.5 million in cash and cash equivalents and $1,049.7 million in available-for-sale debt securities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by exceptional revenue and profit growth, successful product launches, and a significant strategic acquisition, despite increased operating expenses.

Positives

• Net income surged to $197.9 million, a significant improvement from $7.9 million in Q1 2025.
• Total revenues increased by 43.9% to $814.5 million.
• Net product sales grew by 43% to $811.0 million, driven by strong performance of INGREZZA and the successful launch of CRENESSITY.
• INGREZZA sales increased to $656.9 million, demonstrating continued demand.
• CRENESSITY sales reached $153.3 million in its first full quarter post-launch, indicating strong market adoption.
• Cash flow from operating activities improved significantly to $145.8 million.
• The company successfully completed the sale of Neurocrine Group Limited, generating $63.2 million in cash and a $28.6 million gain.
• The acquisition of Soleno Therapeutics for $2.9 billion, if completed, represents a significant strategic move to expand the pipeline.
• The company's disclosure controls and procedures were deemed effective.

Negatives

• Operating expenses increased to $621.1 million, driven by higher R&D and SG&A costs.
• Research and development expenses increased to $296.2 million, reflecting continued investment in pipeline development.
• Selling, general, and administrative expenses rose to $318.5 million, due to investments in commercial organization expansion.
• Cash flows from investing activities showed a significant outflow of $506.2 million, primarily due to purchases of available-for-sale debt securities.
• The company has a significant contingent liability of up to $15.39 billion in potential future payments related to collaboration and license agreements.

Risks

• The company faces intense competition in the pharmaceutical industry, with competitors having greater resources and experience.
• Government and third-party payors may impose pricing controls or limit coverage and reimbursement for products, impacting revenue.
• Clinical trials may be delayed or fail to demonstrate safety and efficacy, preventing or delaying regulatory approval.
• The company is transforming its R&D strategy to include biologics, which requires substantial investment and carries inherent risks.
• The pending acquisition of Soleno Therapeutics is subject to customary closing conditions and may not be completed.
• The company depends on a limited number of third-party suppliers for manufacturing, and any disruption could adversely affect supply.
• The company faces risks related to intellectual property protection, with competitors potentially developing products based on its discoveries.
• The company's customers are concentrated, and the loss of a significant customer could harm its business.
• The company may need additional capital in the future, and there is no guarantee it will be available on favorable terms.
• The company faces legal proceedings, including a patent infringement suit related to INGREZZA and a DOJ investigation into sales and marketing of INGREZZA.
• The company's stock price is volatile and subject to market fluctuations and analyst expectations.
• The company is subject to stringent and changing data privacy and information security obligations.

Future Outlook

The company believes its existing capital resources, anticipated product sales, and investment income will be sufficient to meet funding requirements for at least the next 12 months. However, it may seek additional funding through equity or debt markets if conditions are favorable. The acquisition of Soleno Therapeutics is expected to close in the second quarter of 2026 and will be funded with cash on hand, significantly reducing cash and investment balances. The company also plans to optimize its capital structure with modest debt.

Management Comments

• "Total net product sales for the first quarter of 2026 increased $247.3 million, or 43.9%, to $811.0 million, reflecting increased net product sales of CRENESSITY... and INGREZZA, driven primarily by volume growth and record new prescriptions on strong patient demand."
• "Promoted Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies."
• "We expect to fund the transaction with cash on hand and available investments, which would significantly reduce our cash, cash equivalents and investment balances."

Industry Context

StockSavvy.ai notes that Neurocrine Biosciences' strong Q1 2026 performance aligns with a trend of increasing demand for specialized neurological and psychiatric treatments. The significant revenue growth, particularly from INGREZZA and the successful launch of CRENESSITY, highlights the company's ability to capture market share in its therapeutic areas. The aggressive acquisition strategy, exemplified by the Soleno Therapeutics deal, reflects a broader industry trend of consolidation and pipeline expansion through M&A to secure future growth drivers.

Comparison to Industry Standards

• Neurocrine's revenue growth of 43.9% in Q1 2026 significantly outpaces the average revenue growth for mid-cap biotechnology companies, which typically ranges from 10-20% annually.
• The net income margin of approximately 24.3% ($197.9M / $814.5M) is strong for the biopharmaceutical sector, where margins can vary widely but often fall within the 10-25% range for established companies with successful products.
• The R&D spend as a percentage of revenue (36.4%) is consistent with industry standards for companies in the development and commercialization phases, indicating a commitment to pipeline advancement.
• The company's cash and cash equivalents of $266.5 million, combined with available-for-sale debt securities of $1,049.7 million, provide substantial liquidity, exceeding the typical cash reserves of many smaller biotech firms and positioning it well for strategic investments like the Soleno acquisition.

Management Changes

Legal Proceedings

• Neurocrine Biosciences received a notice from Zydus Lifesciences Global FZE regarding an ANDA for a generic version of INGREZZA SPRINKLE, alleging patent invalidity and non-infringement. Neurocrine filed suit against Zydus for patent infringement.
• Neurocrine Biosciences received a civil investigative demand from the U.S. Department of Justice (DOJ) requesting documents and information related to its sales and marketing of INGREZZA. The company is cooperating with the investigation.

Related Party Transactions

• As part of the 2023 Voyager Agreement, Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors. Dr. Onyia (or another designated individual) will be nominated annually for a maximum of 10 years. Neurocrine's equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party after Neurocrine acquired 2023 Voyager Shares, owning approximately 19.9% of Voyager's voting stock.

Stakeholder Impact

• Shareholders: Positive impact due to significant increase in net income, revenue, and EPS, and the strategic acquisition of Soleno Therapeutics, which is expected to enhance future growth.
• Employees: Positive impact from the promotion of Andrew Ratz, Ph.D., and continued investment in commercial and R&D teams, indicating company growth and expansion.
• Customers (Patients): Continued access to INGREZZA and CRENESSITY, with potential future treatments from the acquired Soleno pipeline.
• Creditors: The company's strong liquidity and cash flow from operations suggest a stable ability to meet financial obligations.

Next Steps

• Complete the acquisition of Soleno Therapeutics, Inc.
• Continue to maximize opportunities for INGREZZA and CRENESSITY through commercial execution.
• Continue development of valbenazine for new patient populations.
• Lead the evolving understanding of VMAT2 biology.
• Continue development of NBI-1117570 in Phase 2 studies for schizophrenia.
• Continue development of osavampator in Phase 3 studies for MDD.
• Continue development of NBI-921355 in Phase 1 studies for epilepsy.
• Expand capabilities in biologics (peptides, antibodies) and gene therapy.
• Continue to manage and potentially expand the sales force for INGREZZA and CRENESSITY.

Key Dates

Recommendation

The company delivered exceptionally strong Q1 2026 results with significant revenue and net income growth, driven by its key products INGREZZA and CRENESSITY. The successful launch and rapid uptake of CRENESSITY, coupled with continued strength in INGREZZA, demonstrate robust commercial execution. Furthermore, the pending $2.9 billion acquisition of Soleno Therapeutics signals a strategic commitment to pipeline expansion and future growth, supported by a strong balance sheet. While operating expenses are increasing, they are in line with growth initiatives and pipeline development. The legal risks, while present, appear manageable given the company's current assessment. The overall financial performance and strategic direction warrant a strong buy recommendation.

Keywords

Neurocrine Biosciences, 10-Q, Quarterly Report, INGREZZA, CRENESSITY, Valbenazine, Crincecerfont, Tardive Dyskinesia, Congenital Adrenal Hyperplasia, Financial Results, SEC Filing, Pharmaceuticals, Biotechnology, Soleno Therapeutics Acquisition